Perioperative chemotherapy with FLOT improved overall survival in patients with resectable esophageal cancer compared with neoadjuvant chemoradiation with CROSS. #ASCO24

oncnursingnews.com/view/periopera…

Patients with HR-positive, HER2-low, and -ultralow metastatic breast cancer treated with trastuzumab deruxtecan obtained a PFS benefit vs chemotherapy. #ASCO24

oncnursingnews.com/view/t-dxd-ext…

Patients with advanced non-small cell lung cancer who received palliative care via telehealth had similar improvements in quality of life as those who received the care through in-person visits. #ASCO24

oncnursingnews.com/view/telehealt…

The combination given before lymph node dissection and response-driven adjuvant therapy reduced the risk for recurrence, progression, or death in stage III melanoma. #ASCO24

oncnursingnews.com/view/neoadjuva…

Adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer. #ASCO24

oncnursingnews.com/view/lymphaden…

Triplet therapies containing belantamab mafodotin, pomalidomide, and dexamethasone may address an unmet need for relapsed/refractory multiple myeloma. #ASCO24

oncnursingnews.com/view/belantama…

The survival benefit obtained from consolidation treatment with durvalumab after concurrent chemoradiation may change the standard of care for limited-stage small cell lung cancer. #ASCO24

oncnursingnews.com/view/consolida…

Compared with placebo, osimertinib after definitive chemoradiotherapy improved progression-free survival in locally advanced, EGFR-mutated non–small cell lung cancer. #ASCO24

oncnursingnews.com/view/osimertin…

Patients with refractory EGFR-mutated, advanced non-small lung cancer had improved responses with low rates of adverse effects with subcutaneous amivantamab vs its intravenous formulation. #ASCO24

oncnursingnews.com/view/subcutane…

Updated data from the MANIFEST-2 study support a paradigm shift in the treatment of JAK inhibitor–naive patients with myelofibrosis. #ASCO24

oncnursingnews.com/view/pelabresi…

Dabrafenib (Tafinlar) plus trametinib (Mekinist) continued to demonstrate improved survival compared with placebo for the adjuvant treatment of patients with stage III melanoma. #ASCO24

oncnursingnews.com/view/adjuvant-…

Frontline amivantamab plus lazertinib outperformed osimertinib regarding progression-free survival in patients with high-risk EGFR-mutant non-small cell lung cancer. #ASCO24

oncnursingnews.com/view/amivantam…

A brentuximab vedotin-containing regimen led to “unprecedented” progression-free survival improvements in patients with advanced classical Hodgkin lymphoma. #ASCO24

oncnursingnews.com/view/brentuxim…

Asciminib led to a superior 48-week major molecular response rate compared with investigator-selected tyrosine kinase inhibitors for Ph-positive chronic phase chronic myeloid leukemia. #ASCO24

oncnursingnews.com/view/asciminib…

Lorlatinib, compared with crizotinib, prolonged PFS and improved time to intracranial progression in ALK-positive non–small cell lung cancer. #ASCO24

oncnursingnews.com/view/lorlatini…

The FDA approved lisocabtagene maraleucel (liso-cel; Breyanzi) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma treated with at least 2 prior lines of systemic therapy including a BTK inhibitor.

oncnursingnews.com/view/fda-appro…

Patients with advanced clear cell renal cell carcinoma who received salvage treatment with nivolumab plus ipilimumab after progressing on nivolumab alone had significant treatment-free survival rates.

oncnursingnews.com/view/salvage-t…

Selpercatinib was granted accelerated approval from the FDA for patients aged 2 years and older with thyroid cancer or solid tumors with RET mutations.

oncnursingnews.com/view/fda-appro…

Six-year administration of imatinib maintenance therapy—compared with the standard 3 years—improved disease-free survival in gastrointestinal stromal tumors.

oncnursingnews.com/view/adjuvant-…

Oncology nurses can educate patients about the availability of pre-exposure prophylaxis for preventing COVID-19.

oncnursingnews.com/view/opinion-o…